HomeInsightsStock Comparison

Alkem Laboratories Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Alkem Laboratories Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 18, 2025

Key Highlights

  • The Latest Trading Price of Alkem Laboratories Ltd is ₹ 5221 as of 16 May 15:30.
  • The P/E Ratio of Alkem Laboratories Ltd changed from 24.7 on March 2020 to 32.9 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 226.4 on March 2020 to 55.8 on March 2024 . This represents a CAGR of -24.43% over 5 years.
  • The Market Cap of Alkem Laboratories Ltd changed from ₹ 27844 crore on March 2020 to ₹ 59067 crore on March 2024 . This represents a CAGR of 16.23% over 5 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 21095 crore on March 2020 to ₹ 32917 crore on March 2024 . This represents a CAGR of 9.31% over 5 years.
  • The revenue of Alkem Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 3467 crore. This represent the decline of -100% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 1015 crore as compare to the Dec '24 revenue of ₹ 984.49 crore. This represent the growth of 3.1%.
  • The ebitda of Alkem Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 852.38 crore. This represent the decline of -100% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 373.87 crore as compare to the Dec '24 ebitda of ₹ 326.99 crore. This represent the growth of 14.34%.
  • The net profit of Alkem Laboratories Ltd changed from ₹ 287.81 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 132.25 crore to ₹ 262.87 crore over 8 quarters. This represents a CAGR of 40.98% .
  • The Dividend Payout of Alkem Laboratories Ltd changed from 23.64 % on March 2020 to 27.37 % on March 2024 . This represents a CAGR of 2.97% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 615.76 % on March 2020 to 92.72 % on March 2024 . This represents a CAGR of -31.52% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alkem Laboratories Ltd

  • Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations.
  • The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
  • The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets.
  • With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales.
  • The company also has presence in more than 40 international markets, with the United States being its key focus market. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988.

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. The Company's portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease.
  • Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases.

Alkem Laboratories Ltd News Hub

News

Alkem Laboratories to discuss results

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 29 May ...

Read more

17 May 2025 15:23

News

Alkem MedTech acquires Bombay Ortho Industries

Alkem Laboratories announced that its wholly owned subsidiary, Alkem MedTech has completed...

Read more

17 Apr 2025 09:43

News

Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho

In February this year, Alkem Medtech had executed a binding offer outlining the terms and ...

Read more

17 Apr 2025 14:49

News

Alkem Lab gains as Bioequivalence Center clears USFDA inspection without observations

The inspection, conducted from March 10 to March 13, 2025, concluded that no Form 483 had ...

Read more

17 Mar 2025 09:57

News

Alkem Lab's Bioequivalence Center clears USFDA inspection without observations

The inspection concluded that no Form 483 had been issued. Alkem Laboratories is engaged i...

Read more

15 Mar 2025 12:44

News

Alkem Laboratories launches generic empagliflozin in India

Alkem Laboratories announced the launch of generic empagliflozin and its combinations in I...

Read more

12 Mar 2025 10:26

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same per...

Read more

14 May 2025 12:47

News

GlaxoSmithKline Pharmaceuticals AGM scheduled

GlaxoSmithKline Pharmaceuticals announced that the Annual General Meeting(AGM) of the comp...

Read more

13 May 2025 17:18

News

Board of GlaxoSmithKline Pharmaceuticals recommends final dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

13 May 2025 17:18

News

GlaxoSmithKline Pharmaceuticals to conduct board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

19 Apr 2025 09:56

News

Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmala...

Read more

06 Feb 2025 12:00

News

GlaxoSmithKline Pharmaceuticals revises board meeting date

GlaxoSmithKline Pharmaceuticals has revised the meeting of the Board of Directors which wa...

Read more

21 Jan 2025 11:16

SWOT Analysis Of Alkem Laboratories Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Alkem Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Alkem Laboratories Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Alkem Laboratories Ltd is 62,424 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 47,901 Cr

What are the key factors driving the stock performance of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 18, 2025, the Alkem Laboratories Ltd stock price is INR ₹5221.0. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2827.6.

How do dividend payouts of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions